Home Biosimilar Antibodies Metabolism PCSK9 Ongericimab (Anti-PCSK9)
For research use only. Not for use in humans.

Ongericimab (Anti-PCSK9)

Synonyms: JS002

Ongericimab (Anti-PCSK9) is a humanized monoclonal antibody targeting PCSK9. It has lipid-lowering efficacy and can be used in research of hypercholesteremia and hyperlipidemia. MW :143.04 KD.

Ongericimab (Anti-PCSK9)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet

Specificity

Name Citation PCSK9
PF-06446846 0
PF-06446846 hydrochloride 0
SBC-110736 0
R-IMPP 0
SBC-115076 9
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ongericimab (Anti-PCSK9) is a humanized monoclonal antibody targeting PCSK9. It has lipid-lowering efficacy and can be used in research of hypercholesteremia and hyperlipidemia. MW :143.04 KD.
References

Product Details

CAS No. 2145096-91-7
Molecular Weight 143.04
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.